Volume 5, Issue 3
WUT-AMU Institute, Wuhan University of Technology, Wuhan, Hubei, 430070, China
Published：30 September 2025
Scan QR Code
Feng Jiaying.DNA Methylation in the Regulation and Clinical Application of HER2-Positive Breast Cancer[J].Biomedical Data Science,2025,05(03):78-81.
Feng Jiaying.DNA Methylation in the Regulation and Clinical Application of HER2-Positive Breast Cancer[J].Biomedical Data Science,2025,05(03):78-81. DOI： 10.47297/wspbdsWSP2752-630515.20250503.
HER2-positive breast cancer represents an aggressive form of the disease driven by excessive HER2 protein expression or genetic amplification
leading to accelerated tumor growth
heightened metastatic potential
and unfavorable clinical outcomes. Epigenetic dysregulation plays a pivotal role in the pathogenesis of this malignancy
with aberrant DNA methylation patterns serving as one of the key molecular hallmark. These methylation-based biomarkers hold promise for improving diagnostic accuracy
predicting disease outcomes
and assessing treatment efficacy in HER2-positive tumors. Consequently
investigating the relationship between methylation anomalies and disease progression in this subtype is critical for advancing translational research. This review comprehensively examines the molecular signatures and mechanistic underpinnings of DNA methylation dysregulation in HER2-positive breast cancer
its correlation with HER2 overexpression
and its clinical utility. By synthesizing current evidence and prospecting future research directions
this discussion aims to guide future studies and facilitate the development of epigenetically targeted interventions.
T. Yamaguchi , H. Mukai , S. Yamashita , S. Fujii , and T. Ushijima , " Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer ," Oncology , vol. 88 , no. 6 , pp. 377 – 384 , 2015 .
A. Nishiyama and M. Nakanishi , " Navigating the DNA methylation landscape of cancer ," Trends in Genetics , vol. 37 , no. 11 , pp. 1012 – 1027 , Nov. 2021 .
N. Iqbal and N. Iqbal , " Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications ," Molecular Biology International , vol. 2014 , pp. 1 – 9 , Sep. 2014 .
Z. Zhou and D . G ., "HER2 Amplification or Overexpression in Upper GI Tract and Breast Cancer with Clinical Diagnosis and Treatment," in Oncogene and Cancer - From Bench to Clinic , Y. Siregar, Ed., InTech, 2013 .
K . Terada et al ., " Association between frequent CpG island methylation and HER2 amplification in human breast cancers ," Carcinogenesis , vol. 30 , no. 3 , pp. 466 – 471 , Mar. 2009 .
H . Fieglet al ., " Breast Cancer DNA Methylation Profiles in Cancer Cells and Tumor Stroma: Association with HER-2/neu Status in Primary Breast Cancer ," Cancer Research , vol. 66 , no. 1 , pp. 29 – 33 , Jan. 2006 .
Q . Liu et al ., " A novel HER2 gene body enhancer contributes to HER2 expression ," Oncogene , vol. 37 , no. 5 , pp. 687 – 694 , Feb. 2018 .
M . Ansar et al., "Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer," Front. Oncol. , vol. 12 , Nov. 2022 .
X. Xie , S. Tang , and Z. Yu , " DNA Methylation-Regulated HOXC8's Role in HER2-Positive Breast Cancer Function and its Contribution to Herceptin Resistance ," Discovery Medicine , vol. 36 , no. 182 , pp. 559 – 570 , Mar. 2024 .
B. M. Lindqvist , S. Wingren , P. B. Motlagh , and T. K. Nilsson , " Whole genome DNA methylation signature of HER2-positive breast cancer ," Epigenetics , vol. 9 , no. 8 , pp. 1149 – 1162 , Aug. 2014 .
D . Furrer et al ., " Association between genome-wide epigenetic and genetic alterations in breast cancer tissue and response to HER2-targeted therapies in HER2-positive breast cancer patients: new findings and a systematic review ," Cancer Drug Resist , vol. 5 , pp. 995 – 1015 , 2022 .
"Downregulation of Dkk3 activates β-catenin/TCF-4 signaling in lung cancer | Carcinogenesis | Oxford Academic ." Accessed: May 05, 2025 . [Online ] . Available: https://academic.oup.com/carcin/article/29/1/84/2476863?login=true https://academic.oup.com/carcin/article/29/1/84/2476863?login=true
W . Ruan et al ., " IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis," Cancer Biol. Ther. , vol. 6 , no. 3 , pp. 354 – 359 , Mar. 2007 .
P.-K . Lo , J. S. Lee , X. Liang , and S. Sukumar , " The dual role of FOXF2 in regulation of DNA replication and the epithelial-mesenchymal transition in breast cancer progression ," Cellular Signalling , vol. 28 , no. 10 , pp. 1502 – 1519 , Oct. 2016 .
N . Arai et al ., " HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity ," Breast Cancer Res Treat , vol. 201 , no. 2 , pp. 317 – 328 , Sep. 2023 .
B. M. Lindqvist , Farkas , Sanja A. , Wingren , Sten , and T. K. Nilsson , " DNA methylation pattern of the SLC 25A43 gene in breast cancer ," Epigenetics, vol. 7 , no. 3 , pp. 300 – 306 , Mar. 2012 .
S . Fujii et al ., " Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation ," Oncotarget , vol. 8 , no. 12 , pp. 19039 – 19048 , Mar. 2017 .
M . Rasool et al., "The role of epigenetics in personalized medicine: challenges and opportunities," BMC Medical Genomics , vol. 8 , no. 1 , p. S 5 , Jan. 2015.
S . Palomeraset al ., "Abstract 2130A: Epigenetic silencing of TGFβ1, BCL6, KILLIN and CTSZ is related to trastuzumab resistance in HER2-positive breast cancer models," Cancer Research , vol. 76 , no. 14_Supplement, p. 2130 A , Jul. 2016 .
Y.-T . Huang et al ., " PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy ," J Transl Med , vol. 11 , no. 1 , p. 245 , Dec. 2013 .
Y. Jiang , L. Cui , W. Chen , S. Shen , and L. Ding , " The Prognostic Role of RASSF1A Promoter Methylation in Breast Cancer: A Meta-Analysis of Published Data ," PLoS One , vol. 7 , no. 5 , p. e36780, May 2012 .
S . Dou et al ., " Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy ," Journal of Controlled Release , vol. 161 , no. 3 , pp. 875 – 883 , Aug. 2012 .
Li Yuan , Lu Yuxiang , Chu Yuankui , and Yang Hua , " Decitabine regulates the expression and mechanism of miR-1301- 3 p in breast cancer cells through DNA methylation ," Chinese Journal of Hospital Pharmacy, vol. 44 , no. 24 , pp. 2839 – 2844 , 2024.
L . Ren et al ., " Enhancing antitumor activity of herceptin in HER2-positive breast cancer cells: a novel DNMT-1 inhibitor approach ," Discov Onc , vol. 15 , no. 1 , p. 640 , Nov. 2024 .
Related Articles
Related Author
Related Institution
京公网安备11010802024621